Durvalumab vs Liraglutide

Durvalumab vs Liraglutide: Overview

This comparison examines the pharmacological differences between Durvalumab and Liraglutide.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Liraglutide: GLP-1 receptor agonist enhancing insulin secretion.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Liraglutide — 13 hours.

Chemical Properties

Type: Durvalumab — Antibody; Liraglutide — Protein.